Ascletis Pharma Inc.
1672
Classement en actions
#10749
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Prix de l'action
$0.70092358
Capitalisation boursière
$735.73M
Changement (1 jour)
-7.64%
Changement (1 an)
-39.58%
Pays
CN
Échange Ascletis Pharma Inc. (1672)
Catégorie
Healthcare
Historique du prix de l'action pour Ascletis Pharma Inc. (1672)
Prix de clôture le plus élevé : $0.92 le 2026-10-01
Prix de clôture le plus bas : $0.60 le 2019-11-01
Prix de clôture le plus bas : $0.60 le 2019-11-01
Historique du prix de l'action de Ascletis Pharma Inc. de 2019 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -10.71% |
| 2025 | 759.36% |
| 2024 | 9.90% |
| 2023 | -65.45% |
| 2022 | 11,939.80% |
| 2021 | -98.81% |
| 2020 | -40.55% |
| 2019 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.24 | 7.63% |
CH
|
